Apimeds Pharmaceuticals US Enters Agreement to Acquire Apitox Rights

What Happened

• On August 19, 2026, Apimeds Pharmaceuticals US, Inc. entered an Assignment and Transfer Agreement with FreeT Inc. under which FreeT irrevocably assigned certain Apitox-related rights (the “Assigned Rights”) to Apimeds. The Assigned Rights derive from a prior Apitox Rights Transfer Agreement dated June 16, 2015.
• FreeT confirmed it will support continued development and potential global transactions to grant Apitox rights outside the U.S., subject to separate agreements. The Assignment Agreement is governed by the laws of the Republic of Korea, with exclusive jurisdiction in the Seoul Central District Court. A copy of the agreement is filed as Exhibit 10.1 to the Form 8-K.

Key Details

• Effective date of assignment: August 19, 2026.
• Allocation of rights: 100% of rights for the Apitox market for Korean medicine clinics in the Republic of Korea.
• Financial participations: 25% royalty entitlement on economic proceeds from U.S. development/licensing/commercialization of Apitox; 25% revenue participation on net proceeds from overseas rights agreements.
• Limits/exclusions: Assignment limited to rights FreeT actually held and legally could assign; expressly excludes any global rights not held by FreeT, ownership of underlying Apitox intellectual property, and other indication-, territory-, manufacturing-, regulatory- or commercialization-specific rights not granted to FreeT. Apimeds does not assume pre-effective-date liabilities under the 2015 Agreement.

Why It Matters

• For investors, the deal gives Apimeds direct contractual claims to specific Apitox revenue streams (notably 25% U.S. royalties and 25% overseas revenue participation) and exclusive Korean clinic market rights, which could provide future revenue if Apitox is commercialized.
• The assignment is limited in scope (it does not convey IP or broad global rights) and additional agreements would likely be needed to secure wider territorial or manufacturing rights. The agreement’s governance under Korean law and the Seoul court may affect dispute resolution and enforcement.